Cytori’s Current Valuations Are Attractive, Says Roth Capital
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a few insights on Cytori Therapeutics Inc (NASDAQ:CYTX), as the company announced that the first patient has been treated in its Phase II ACTOA study of Cytori Cell Therapy in osteoarthritis (OA) patients. The analyst rates the stock a Buy with a $6 price target, which implies an upside of 1150% from current levels.
Pantginis noted, “We’re encouraged by the progress in the OA program, which aims to develop a novel therapeutic opportunity to OA patients who have limited non-surgical options. Such a new therapy could help not only the patients’ well being and expand the arsenal for treating physicians, but also help unburden the healthcare system from costs associated with OA such as ambulatory care and hospitalizations, including total knee replacements.”
The analyst continued, “We believe there is significant potential opportunity for Cytori’s approach, should the product reach the market, based on these factors and on the high prevalence of OA in the U.S. We believe that treating orthopedic doctors are in need of new nonsurgical procedures to treat their patients as current available options are not satisfactory.”
Bottom line, “We continue to view Cytori as a leading regenerative medicine player and believe current valuations are attractive following a “re-boot” of the company.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of 4.6% and a 50.5% success rate. Pantginis has a -40.4% average return when recommending CYTX, and is ranked #655 out of 3476 analysts.